CME Information
This activity is provided by The France Foundation.
This educational activity is intended for geneticists, genetic counselors, pediatricians, neurologists, and other members of the health care team who care for patients with Lysosomal Storage Diseases.
This activity will focus on the historical, current, and future use of biomarkers to diagnose, treat, and monitor patients with Lysosomal Storage Diseases, or LSDs.
Upon completion of this activity, the learners should be able to:
- Describe the history and evolution of biomarkers in the diagnosis and monitoring of Lysosomal Storage Diseases (LSDs)
- Appraise the value of new and emerging disease-specific biomarkers to detect early pathologies, track disease progression, and monitor response to therapy
- Evaluate how omics-driven biomarker development strategies can support clinical decision-making and personalization efforts in GD (Gaucher disease), MPS II (Mucopolysaccharidosis type II), and MLD (Metachromatic leukodystrophy)
FACULTY
Barbara K. Burton, MD (Chair)
Attending Physician, Genetics, Birth Defects, and Metabolism
Professor of Pediatrics (Genetics, Birth Defects, and Metabolism)
Northwestern University Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Priya Kishnani, MD, MBBS
Chen Family Distinguished Professor of Pediatrics
Chief, Division of Medical Genetics
Duke University School of Medicine
Durham, NC
Marc Patterson, MD
Professor of Neurology, Pediatrics, and Medical Genetics
Chair, Division of Child and Adolescent Neurology
Mayo Clinic
Rochester, MN
PLANNING COMMITTEE
Barbara K. Burton, MD (Chair)
Attending Physician, Genetics, Birth Defects, and Metabolism
Professor of Pediatrics (Genetics, Birth Defects, and Metabolism)
Northwestern University Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Priya Kishnani, MD, MBBS
Chen Family Distinguished Professor of Pediatrics
Chief, Division of Medical Genetics
Duke University School of Medicine
Durham, NC
Marc Patterson, MD
Professor of Neurology, Pediatrics, and Medical Genetics
Chair, Division of Child and Adolescent Neurology
Mayo Clinic
Rochester, MN
Patrick Harty, PhD
Director of Medical Education
The France Foundation
Old Lyme, CT
ACCREDITATION STATEMENT
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other healthcare professionals completing this course will be issued a statement of participation.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.
Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Disclosures
The following financial relationships have been disclosed:
|
Name and Affiliation |
Role in Activity |
Name of Commercial Entity |
Nature of Relationship(s) |
Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity |
|
Barbara K. Burton, MD |
Planning Committee Member, Faculty |
1. Aeglea, Applied Therapeutics, Aro, BioMarin, Capsida, Horizon, JCR Pharma, Jnana, Moderna, Orchard, Sanofi Genzyme, Takeda, Ultragenyx
2. BioMarin, Horizon, Takeda
3. BioMarin, Homology Medicines, Sangamo, Takeda, Ultragenyx |
1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research |
All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
|
|
Janis Vajdos, MS |
TFF Staff |
No relevant financial relationships |
NA |
NA |
|
Jaspreet Chahal, PhD |
TFF Staff |
No relevant financial relationships |
NA |
NA |
|
Marc Patterson, MD |
Planning Committee Member, Faculty |
1. Azafaros, Glycomine, Maggie’s Pearl, Orphazyme/KemPharm, Takeda |
1. Contract Research |
The financial relationship with Caris Life Sciences ended in November 2022 All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Marc Patterson, MD |
Planning Committee Member, Faculty |
1. Azafaros, Glycomine, Maggie’s Pearl, Orphazyme/KemPharm, Takeda |
1. Contract Research |
All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Patrick Harty, PhD |
Planning Committee Member, TFF Content Reviewer |
No relevant financial relationships |
NA |
NA |
|
Priya Kishnani,
MD, MBBS
|
Planning Committee Chair, Faculty |
1. Sanofi Genzyme, Takeda 2. Sanofi Genzyme 3. Pfizer, Sanofi Genzyme, Takeda 4. Takeda |
1.Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research 4. Advisory Board Member |
All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
|
The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
This activity is supported by an educational grant from Takeda Pharmaceuticals, Inc.
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.
Topic: Lysosomal Storage Diseases (LSD)
Accreditation Type:
Physicians—maximum of 1.0 AMA PRA Category 1 Credit(s)™
ABIM Maintenance of Certification—1 Medical Knowledge Point
Accreditor: The France Foundation
Activity Dates: May 20, 2023 — July 16, 2024
Estimated Time to Complete Activity: 60 Minutes
CONTACT INFORMATION
METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Participate in the CME/CE activity.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- You will receive an email with a link to download your CME/CE certificate following the activity. MOC points will be uploaded to the ABIM within 60 days.
